Tradestie Institutional Equity Comparison Engine

OABI vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while OABI counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OABI trades at N/M Forward P/E with -92.9% operating margin (+78.3% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, OABI sits in SURGE (20th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
OABI N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin -92.9% vs 41.3% ยท YoY +78.3% vs +102.1%
Momentum & Technical Winner OABI
1Y +223.7% vs +23.2% ยท 52W Pos 90% vs 33%
Options & Structure Winner OABI
SURGE (20th %ile IV) vs BREAKDOWN (57th %ile IV)
OABI NASDAQ
OmniAb, Inc. Common Stock
Services-Commercial Physical & Biological Research
$5.05
+3.27% 1D
Market Cap $713.3M
1M Return +7.68%
1Y Return +223.72%
Forward P/E N/M
Unified AI Score
56.2 / 100 HOLD
Tech 50.0 Fund 51.0 Flow 54.0 Mom 50.0
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OABI +223.72% CGEN +23.17% Spread: +200.55 pp (OABI Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OABI Revenue CGEN Revenue OABI Op. Margin CGEN Op. Margin Margin Edge
FY2016 N/A $0M N/A -4576.3% CGEN
FY2018 N/A $20M N/A -130.5% CGEN
FY2020 N/A $0M N/A -1574.8% CGEN
FY2021 $30M $10M -102.5% -584.6% OABI
FY2022 $60M $10M -45.1% -471.7% OABI
FY2023 $30M $30M -203.2% -38.8% CGEN
FY2024 $30M $30M -282.3% -53.4% CGEN
FY2025 $20M $70M -369.5% 43.1% CGEN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OABI (4) vs CGEN (6)
Institutional Metric OABI CGEN Criterion Row Winner
Market Capitalization Scale $713.3M $193.2M Larger Scale OABI
Trailing P/E Ratio Valuation N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY) Growth +78.3% +102.1% Higher Growth CGEN
Operating Margin (TTM) Profitability -92.9% 41.3% Higher Margin CGEN
Net Profit Margin Profitability -108.1% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -16.5% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 90% ($1โ€“$5) 33% ($1โ€“$3) Stronger Trend OABI
Beta / 30D Volatility Risk Regime 1.23ฮฒ ยท 57% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk OABI
Unified Institutional Score Composite Signal 56.2 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite OABI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OABI vs CGEN Buy Guide
OABI SURGE
14d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live OABI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OABI nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.